Article

Oncogenic drivers dictate immune control of acute myeloid leukemia

2023-02-10

Abstract excerpt

Acute myeloid leukemia (AML) is a genetically heterogeneous, aggressive hematological malignancy induced by distinct oncogenic driver mutations. The effect of specific AML oncogenes on immune activation or suppression has not been investigated. Here, we examine immune responses in genetically distinct models of AML and demonstrate that specific AML oncogenes dictate immunogenicity, the quality of immune response a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f792af86-570d-59fe-8644-22bc3d01c49a
DOI: 10.1101/2023.02.08.527448

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Oncogenic drivers dictate immune control of acute myeloid leukemiaDOI 10.1101/2023.02.08.527448Read

The interaction between common genetic mutations in AML and the immune landscape: mechanisms and implications for immune responseSemantic proximity Read

Coordinated Immune Cell Networks in the Bone Marrow Microenvironment Define the Graft versus Leukemia Response with Adoptive Cellular TherapySemantic proximity Read

Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.Semantic proximity Read

Evolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational PerspectiveSemantic proximity Read

Multi-omics analysis identifies an M-MDSC-like immunosuppressive phenotype in lineage-switched AML with KMT2A rearrangementSemantic proximity Read

Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemiaSemantic proximity Read

Elucidating the Role of the T Cell Receptor Repertoire in Myelodysplastic Neoplasms and Acute Myeloid LeukemiaSemantic proximity Read

Opportunities for immunotherapy in childhood acute myeloid leukemia.Semantic proximity Read

Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia.Semantic proximity Read

Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.Semantic proximity Read

Hematopoietic p53 loss cell-extrinsically defines an immune infiltrated microenvironment in leukemia and pre-leukemiaSemantic proximity Read

Therapy-induced senescence upregulates antigen presentation machinery and triggers anti-tumor immunity in Acute Myeloid LeukemiaSemantic proximity Read